An international team of researchers has, for the first time, created a detailed map of the location and identity of individual cells in the adult lung, both from healthy lungs and in lungs from ...
A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...
The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...
Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback